Tff Pharmaceuticals Inc
TFFP
Get informed when a big investor buys or sells
+ FollowCurrent Fair Value
8520.5% upsideUndervalued by 8520.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $288,798.00 |
|---|---|
| Enterprise Value | $-2,014,603.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-11.85 |
| Beta | 1.32 |
| Outstanding Shares | 4,372,458 |
Return
| Return on Equity | -590.38% |
|---|---|
| Return on Assets | -261.68% |
| Return on Invested Capital | -627.05% |
Valuation & Multiples
| P/E Ratio | -0.01 |
|---|---|
| PEG | 0.03 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | -1.13 |
| Enterprise Value to EBIT | 0.1 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | -0.15 |
| Debt to Equity | 0.1 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Tff Pharmaceuticals Inc
4 employeesTFF Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing, or TFF, technology platform. Early testing confirms that...
Relevant Senate Committees
This committee controls taxation policy, which impacts corporate valuations and profitability, and significantly influences drug pricing through entitlement programs like Medicare, which are crucial for the future commercial viability of TFF Pharmaceuticals' products.
This committee directly regulates the FDA, which is responsible for drug approval, and oversees the NIH, a major source of biomedical research funding. These functions are critical to TFF Pharmaceuticals' core business and regulatory pathway.
This committee directly oversees intellectual property and patent law, which is foundational to TFF Pharmaceuticals' patented TFF technology platform. It also influences antitrust laws relevant to potential collaborations with large pharmaceutical partners.